

Form Revision Notice

Study: 6678

From: ACRIN Data Management Department

Date: February 4, 2009 (Updated October 26, 2009)

RE: ACRIN 6678 A0 Form Revision Notice

**Form Title: 6678 A0- Registration/Eligibility Checklist
Version 2, Dated 12/30/2008**

*** Please begin using this version upon gaining IRB approval for amendment 2.**

The following form revision(s) were:

- Revised on: 12/30/2008
- Posted to the ACRIN study website on: 2/4/2009
- Posted to the online web entry system: 10/26/2009
- Distributed and effective: 2/4/2009 (for all sites approved for Amendment #2)

Question #: 28

Description of revision:

Previous question:

Has the participant had a CT or MR scan of the **chest** and upper abdomen (to include liver and adrenal glands) scan within 4 weeks prior to registration?

New question:

Has the participant had a CT or MR scan of the **chest**?

NOTE: If necessary to determine/confirm stage disease, an upper abdomen CT scan (including liver and adrenals) must be performed.

Question #: 45

Description of revision:

Previous question:

Has the participant had laboratory testing (within 4 weeks of registration) that includes at a minimum, complete blood cell count (CBC) with differential, serum, glucose, blood urea nitrogen (BUN), creatinine, and bilirubin (to include at minimum alkaline phosphatase); these tests demonstrate there are no contraindications for chemotherapy and FDG-PET/CT imaging.

New question:

Which treatment arm is the participant being registered to?

- Group A
- Group B
- Group C

Question #: 54

Description of revision:

Previous question:

Will the participant be getting concurrent treatment with bevacizumab (Avastin) at the start of chemotherapy?

New question:

Treatment planned with any targeted or biologic therapy other than bevacizumab or cetuximab? (Exclusion for Groups A and B only)

All prior versions of blank forms in your department should be discarded. For questions, please contact your ACRIN Data Manager at ACRIN Headquarters.